Stephen Brooks - Braxia Scientific Chief Officer
| BRAXF Stock | USD 0 0 33.33% |
Insider
Stephen Brooks is Chief Officer of Braxia Scientific Corp
| Phone | 416-762-2138 |
| Web | https://braxiascientific.com |
Braxia Scientific Management Efficiency
The company has return on total asset (ROA) of (0.2824) % which means that it has lost $0.2824 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0208) %, meaning that it generated substantial loss on money invested by shareholders. Braxia Scientific's management efficiency ratios could be used to measure how well Braxia Scientific manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Philip Stern | Antibe Therapeutics | N/A | |
| Julie ACA | GH Research PLC | 38 | |
| Sarah Longoria | Exicure | 42 | |
| David Lovejoy | Protagenic Therapeutics | N/A | |
| Robert MD | Protagenic Therapeutics | 73 | |
| Elias Papadimas | Exicure | 48 | |
| Anne Johnson | ATAI Life Sciences | 55 | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| John Kanakis | Cybin Inc | 43 | |
| Sara Le | Oxford Nanopore Technologies | N/A | |
| MEng CFA | Antibe Therapeutics | N/A | |
| Michael Abrams | Arch Therapeutics | 53 | |
| Rolando MD | ATAI Life Sciences | 63 | |
| Gordon Sanghera | Oxford Nanopore Technologies | N/A | |
| Florian Brand | ATAI Life Sciences | 37 | |
| Valerie Cros | Cellectis SA | N/A | |
| Christina BBA | Antibe Therapeutics | N/A | |
| Lori Challenger | Cybin Inc | N/A | |
| Christian Angermayer | ATAI Life Sciences | 46 | |
| Jordan Herman | Oxford Nanopore Technologies | N/A | |
| Aaron Bartlone | Cybin Inc | 57 | |
Management Performance
| Return On Equity | -1.02 | |||
| Return On Asset | -0.28 |
Braxia Scientific Corp Leadership Team
Elected by the shareholders, the Braxia Scientific's board of directors comprises two types of representatives: Braxia Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Braxia. The board's role is to monitor Braxia Scientific's management team and ensure that shareholders' interests are well served. Braxia Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Braxia Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua Rosenblat, Chief Officer | ||
| Roger McIntyre, Chairman CEO | ||
| Stephen Brooks, Chief Officer | ||
| Peter Rizakos, G Counsel | ||
| Jason Wolkove, Chief Officer |
Braxia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Braxia Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.02 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (4.42) % | |||
| Current Valuation | 4.7 M | |||
| Shares Outstanding | 240.72 M | |||
| Shares Owned By Insiders | 11.48 % | |||
| Shares Owned By Institutions | 0.34 % | |||
| Price To Book | 0.91 X | |||
| Price To Sales | 4.45 X | |||
| Revenue | 1.49 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Braxia Pink Sheet
Braxia Scientific financial ratios help investors to determine whether Braxia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Braxia with respect to the benefits of owning Braxia Scientific security.